<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45794">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510092</url>
  </required_header>
  <id_info>
    <org_study_id>Im-CAD-001</org_study_id>
    <nct_id>NCT02510092</nct_id>
  </id_info>
  <brief_title>Coronary Artery and Systemic Autoimmune Disease: Diagnostics and Treatment</brief_title>
  <official_title>In Vivo Intravascular Diagnostics and Evaluation of New Therapeutic Modalities in Systemic Autoimmune and Coronary Artery Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University Heart and Vascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Debrecen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Semmelweis University Heart and Vascular Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates in vivo intracoronary imaging using intravascular ultrasound and
      optical coherence tomography and safety and efficacy of new generation fully bioresorbable
      vascular scaffolds in four well defined systemic autoimmune (rheumatoid arthritis, mixed
      connective tissue disease, systemic sclerosis, systemic lupus erythematosus) and concomitant
      coronary disease patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to assess in vivo intracoronary anatomy using intravascular
      ultrasound and optical coherence tomography and assess the efficacy and safety of new
      generation fully bioresorbable vascular scaffolds in a systemic autoimmune and coronary
      heart disease patient population.

      The following four well defined systemic autoimmune entities are linked to increased
      cardiovascular risk: rheumatoid arthritis, mixed connective tissue disease, systemic
      sclerosis and systemic lupus erythematosus. One of the main causes of death in systemic
      autoimmune subjects is cardiovascular disease. In-vivo intracoronary anatomy and pathology
      regarding systemic autoimmune diseases is unknown. Furthermore, all forms of
      revascularization in such patients yield sub-optimal results, with poor outcomes using even
      the most modern drug eluting metallic stents. This may be linked to a long term exaggerated
      chronic inflammation response to the metallic components. Thus, fully bioresorbable vascular
      scaffolds may prove more efficacious in systemic autoimmune subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac and cerebral events</measure>
    <time_frame>From index procedure to 5 years</time_frame>
    <description>Eligible for patients in clinical need for revascularization undergoing percutaneous revascularization with a bioresorbable vascular scaffold</description>
  </primary_outcome>
  <other_outcome>
    <measure>Intravascular ultrasound findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Minimum Lumen Area (MLA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intravascular ultrasound findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Percent Atheroma Volume (PAV)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intravascular ultrasound findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Area Stenosis (AS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intravascular ultrasound findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Negative or positive remodelling index (RI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intravascular ultrasound findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Intimal thickness (IT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intravascular ultrasound findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Calcification Index (CI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Intima to Media ratio (I/M ratio)</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Excentric intima hyperplasia</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Thin Cap Fibroatheroma presence (TCFA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Macrophage infiltration</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Intramural hematoma formation</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Intimal laceration</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Microchannel formation</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography findings in coronaries</measure>
    <time_frame>At index procedure</time_frame>
    <description>Lipid pool formation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Coronary artery diseae with revascularization indicated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with coronary artery disease, that require and are eligible for percutaneous revascularization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coronary artery disease not requiring revascularization</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with coronary artery disease that do not require revascularization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention with new generation fully resorbable scaffold</intervention_name>
    <arm_group_label>Coronary artery diseae with revascularization indicated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18+ years

          -  Signed and dated informed consent form

          -  Manifest autoimmune disease, consisting either of: rheumatoid arthritis or systemic
             lupus erythematosus or systemic sclerosis or mixed connective tissue disease under
             the care of a clinical immunologist

          -  Clinical indication for a coronary angiography as determined by a cardiologist

        Exclusion Criteria:

          -  Age of 75+ years

          -  Glomerular filtration rate of under 30 ml/min

          -  Severely decreased left ventricular function (ejection fraction &lt;35%)

          -  Pregnancy or nursing

          -  Unclear immunological diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>István F Édes, MD PhD</last_name>
      <phone>+36-20-663-2488</phone>
      <email>edes789@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marianna Szabó</last_name>
      <phone>+36-20-663-2480</phone>
      <email>studycenter.sekk4@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>István F Édes, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ágota Hajas, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>July 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
